Hypercholesterolaemia

The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia or familial heterozygous hypercholesterolaemia.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with evolocumab under the National Health Act 1953, section 85 for patients with either:

  • familial homozygous hypercholesterolaemia
  • familial heterozygous hypercholesterolaemia.

Patients must be eligible for the PBS and meet the relevant restrictions criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing evolocumab.

Treatment specifics

For PBS subsidised initial treatment, patients must be treated by a specialist physician.

For continuing PBS subsidised treatment, patients must be treated by or in consultation with a specialist physician. Apply for PBS authority within 6 months of the consultation.

Applications

Initial treatment - familial homozygous hypercholesterolaemia

Apply for initial authority approval to prescribe PBS subsidised evolocumab to treat familial homozygous hypercholesterolaemia in writing and either:

All initial applications must include the completed:

Initial treatment - familial heterozygous hypercholesterolaemia

Apply for initial authority approval to prescribe PBS subsidised evolocumab to treat familial heterozygous hypercholesterolaemia in writing and either:

All initial applications must include a completed:

Initial grandfather treatment

For patients who received non-PBS subsidised evolocumab before 1 November 2018 for familial heterozygous hypercholesterolaemia, apply for initial grandfather authority in writing and either:

All applications must include the completed:

Continuing treatment

To apply for authority for continuing treatment with evolocumab call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 November 2018